tag:blogger.com,1999:blog-8964719845369935777.post509147030206793617..comments2024-03-27T21:23:40.339-04:00Comments on Chemjobber: I don't think medchem will reshore to the US. Do you? Chemjobberhttp://www.blogger.com/profile/15932113680515602275noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-8964719845369935777.post-67548598943906648162012-12-15T08:53:52.723-05:002012-12-15T08:53:52.723-05:00@Anon 9:12AM -
Lilly has been demoting some of the...@Anon 9:12AM -<br />Lilly has been demoting some of their few current US employees to contractor status with lower pay.<br /><br />There fixed that for ya.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8964719845369935777.post-53457369242766116152012-12-14T12:12:14.267-05:002012-12-14T12:12:14.267-05:00Lilly has been replacing overseas contractors with...Lilly has been replacing overseas contractors with 'in-sourced' medicinal chemistry contractors on-site in US and UK for the last couple of years.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8964719845369935777.post-67431832659349952312012-12-14T10:33:29.176-05:002012-12-14T10:33:29.176-05:00Reshoring MedChem research is already being done.....Reshoring MedChem research is already being done...it's called organic grad school/postdoc.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-8964719845369935777.post-57919031918173774072012-12-14T03:58:43.951-05:002012-12-14T03:58:43.951-05:00Ummm, do BCG people advise their clients to bring ...Ummm, do BCG people advise their clients to bring business home?somedudenoreply@blogger.comtag:blogger.com,1999:blog-8964719845369935777.post-4436713461297117442012-12-13T15:25:31.701-05:002012-12-13T15:25:31.701-05:00My first thought - ten years is a long time. A lot...My first thought - ten years is a long time. A lot can happen, including Black Swans.<br /><br />Still, if reshoring of pharma positions were to happen, it's interesting to speculate about what the driver might be.<br /><br />I recently read an article suggesting that factors unrelated to production costs might be worth considering - specifically the way that outsourcing tends to rapidly transfer know-how and expertise outside of an organization, and in the process create terrifying entities known as "competitors":<br /><br />http://www.asymco.com/2012/12/07/the-real-threat-that-samsung-poses-to-apple/<br /><br />Note that the damage being done has nothing to do with ripping off intellectual property. Rather, it has to do with the outsourcee replicating its benefactor's business process.<br /><br />According to this line of thought, Pharma's recent outsourcing frenzy is nursing to health the very companies that will eat their lunch at some later point. Say, in ten years time?<br /><br />One would have to imagine that more than one or two folks in decision-making capacities would see this starting to happen and take action to reverse course.<br /><br />That might be one scenario for how reshorting could start to happen within the next ten years, but I've seen no evidence for it yet.Rich Apodacahttp://depth-first.comnoreply@blogger.comtag:blogger.com,1999:blog-8964719845369935777.post-22200874068614672252012-12-13T13:52:33.624-05:002012-12-13T13:52:33.624-05:00Maybe not traditional MedChem R&D, but Codexis...Maybe not traditional MedChem R&D, but Codexis recently re-shored its pharma R&D from Singapore (~40 positions). Of course, they laid off 130+ in the States simultaneously, but I suppose it would have been 170+ otherwise...Anonymousnoreply@blogger.com